{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:35Z","timestamp":1791563375910,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd004816.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000}}],"reference-count":293,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004816.pub5","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T08:32:08Z","timestamp":1359448328000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":345,"title":["Statins for the primary prevention of cardiovascular disease"],"prefix":"10.1002","volume":"2021","author":[{"given":"Fiona","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Non-communicable Disease Epidemiology; London School of Hygiene & Tropical Medicine; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D","family":"Huffman","sequence":"additional","affiliation":[{"name":"Departments of Preventive Medicine and Medicine (Cardiology); Northwestern University Feinberg School of Medicine; Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Filipa","family":"Macedo","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences; University of Beira Interior; Covilha Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa HM","family":"Moore","sequence":"additional","affiliation":[{"name":"Population Health Sciences, Bristol Medical School; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burke","sequence":"additional","affiliation":[{"name":"Department of Social Medicine; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Davey Smith","sequence":"additional","affiliation":[{"name":"MRC Integrative Epidemiology Unit, School of Social and Community Medicine; University of Bristol; Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Twin Research & Genetic Epidemiology; King's College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah","family":"Ebrahim","sequence":"additional","affiliation":[{"name":"Department of Non-communicable Disease Epidemiology; London School of Hygiene & Tropical Medicine; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawkins C","family":"Gay","sequence":"additional","affiliation":[{"name":"Northwestern University; Chicago USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjcard.2009.05.020","article-title":"Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force\/Texas Coronary Atherosclerosis Prevention Study)","volume":"104","author":"Cui","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1161\/01.CIR.90.4.1679","article-title":"Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group","volume":"90","author":"Furberg","year":"1994","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.ajkd.2009.09.020","article-title":"Effect of Lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: A post hoc analysis of the Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"55","author":"Kendrick","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0004|cit4","unstructured":"Splichal JE Ornstein DL Hong-Dice YG Downs JR Fischer JR Lovastatin for the prevention of Melanoma: Analysis of AFCAPS\/TexCaps Proceedings of the American Society of Clinical Oncology 2001"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0005|cit5","unstructured":"Brookes L Nakamura H MEGA: Management of elevated cholesterol in the primary prevention group of adult Japanese American Heart Association 2005 Scientific Sessions 2008"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1161\/HYPERTENSIONAHA.108.120584","article-title":"Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA) study","volume":"53","author":"Kushioro","year":"2009","journal-title":"Hypertension"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels Circulation Journal 2004 860 7","DOI":"10.1253\/circj.68.860"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0008|cit8","unstructured":"The role of cardiovascular risk factors in postmenopausal hypercholesterolemic women with abnormal fasting glucose: A post hoc analysis of the MEGA Study Diabetologia 2010"},{"issue":"9542","key":"10.1002\/14651858.CD004816.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.atherosclerosissup.2007.02.003","article-title":"Primary prevention of cardiovascular diseases among hypercholesterolemic Japanese with a low dose of pravastatin","volume":"8","author":"Nakamura","year":"2007","journal-title":"Atherosclerosis Supplements"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0011|cit11","first-page":"18","article-title":"Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study). [Japanese]","volume":"46","author":"Nakamura","year":"2009","journal-title":"Nippon Ronen Igakkai Zasshi - Japanese Journal of Geriatrics"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0021-9150(00)80615-2","article-title":"The design and background characteristics of the study on the primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels (Japanese Mega Study)","volume":"151","author":"Nakamura","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"879","DOI":"10.5551\/jat.4176","article-title":"Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese","volume":"17","author":"Nakaya","year":"2010","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"1-2","key":"10.1002\/14651858.CD004816.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jns.2009.04.002","article-title":"Risk factors for stroke and lipid-lowering effect of Pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: Analysis of data from the MEGA Study, a large randomized controlled trial","volume":"284","author":"Uchiyama","year":"2009","journal-title":"Journal of the Neurological Sciences"},{"issue":"20","key":"10.1002\/14651858.CD004816.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"26","key":"10.1002\/14651858.CD004816.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"New England Journal of Medicine."},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1210\/jc.2006-1909","article-title":"Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: A double-blind, placebo-controlled, dose-ranging trial","volume":"92","author":"Bone","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0021-9150(99)00434-7","article-title":"Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study","volume":"151","author":"Baldassarre","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0002-9343(96)00333-6","article-title":"Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study","volume":"101","author":"Mercuri","year":"1996","journal-title":"American Journal of Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004816.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF01419825","article-title":"Pravastatin intervention trial on carotid artery atherosclerosis in patients with mild hypercholesterolemia: the CAIUS Study","volume":"11","author":"Sirtori","year":"1995","journal-title":"International Journal of Cardiac Imaging"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11883-006-0041-9","article-title":"The CARDS Trial: Diabetic patients dealt a winning hand","volume":"8","author":"Armani","year":"2006","journal-title":"Current Atherosclerosis Reports"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s00125-008-1176-8","article-title":"Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"52","author":"Charlton-Menys","year":"2009","journal-title":"Diabetologia"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1053\/j.ajkd.2009.03.022","article-title":"Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"54","author":"Colhoun","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with Type 2 Diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabetic Medicine"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0027|cit27","first-page":"213","article-title":"Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: A pharmacoeconomic model of the CARDS study","volume":"23","author":"Fernandez De Bobadilla","year":"2006","journal-title":"Anales de Medicina Interna"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/j.1464-5491.2007.02268.x","article-title":"Stroke prediction and stroke prevention with Atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"24","author":"Hitman","year":"2007","journal-title":"Diabetic Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10238-006-0115-6","article-title":"Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes","volume":"6","author":"Jinnouchi","year":"2006","journal-title":"Clinical and Experimental Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004816.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.2337\/dc06-0872","article-title":"Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"29","author":"Neil","year":"2006","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3132\/dvdr.2008.029","article-title":"The safety and tolerability of atorvastatin 10 mg in the collaborative atorvastatin diabetes study (CARDS)","volume":"5","author":"Newman","year":"2008","journal-title":"Diabetes and Vascular Disease Research"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00019053-200826040-00005","article-title":"An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes","volume":"26","author":"Ramsey","year":"2008","journal-title":"PharmacoEconomics"},{"issue":"6987","key":"10.1002\/14651858.CD004816.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.310.6987.1105","article-title":"The impact of health care advice given in primary care on cardiovascular risk","volume":"310","author":"Lindholm","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2796.1996.492831000.x","article-title":"Changes in cardiovascular risk factors by combined pharmacological strategies: the main results of the CELL Study","volume":"240","author":"Lindholm","year":"1996","journal-title":"Journal of Internal Medicine"},{"issue":"6987","key":"10.1002\/14651858.CD004816.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/bmj.310.6987.1105","article-title":"The impact of health care advice given in primary care on cardiovascular risk","volume":"310","author":"Lindholm","year":"1995","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2796.1996.492831000.x","article-title":"Changes in cardiovascular risk factors by combined pharmacological and nonpharmacological strategies: the main results of the CELL Study","volume":"240","author":"Lindholm","year":"1996","journal-title":"Journal of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.2337\/diacare.28.7.1675","article-title":"No effect of statin therapy on silent myocardial ischemia in patients with Type 2 diabetes without manifest cardiovascular disease","volume":"28","author":"Beishuizen","year":"2005","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.2337\/diacare.28.7.1668","article-title":"The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease","volume":"28","author":"Beishuizen","year":"2005","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2337\/diacare.27.12.2887","article-title":"Two year statin therapy does not alter the progression of intima medica thickness in patients with type 2 diabetes without manifest cardiovascular disease","volume":"27","author":"Beishuizen","year":"2004","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0149-2918(03)80070-X","article-title":"Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet","volume":"25","author":"Derosa","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14017430701411234","article-title":"Effect of lifestyle and\/or statin treatment on soluble markers of atherosclerosis in hypertensives","volume":"41","author":"Hjelstuen","year":"2007","journal-title":"Scandanavian Cardiovascular Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0042|cit42","first-page":"387","article-title":"Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives","volume":"178","author":"Sigmund","year":"2004","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2011.03.032","article-title":"Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of statins in Prevention: An interventionTrial Evaluating Rosuvastatin (JUPITER) trial","volume":"162","author":"Albert","year":"2011","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0044|cit44","unstructured":"Bloom JM Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0045|cit45","unstructured":"Danchin N Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0046|cit46","unstructured":"Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","article-title":"Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER)","volume":"121","author":"Everett","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0048|cit48","unstructured":"Feeman Jr WE Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"issue":"9","key":"10.1002\/14651858.CD004816.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1586\/erc.09.93","article-title":"Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study","volume":"7","author":"Fonseca","year":"2009","journal-title":"Expert Review of Cardiovascular Therapy"},{"issue":"18","key":"10.1002\/14651858.CD004816.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa0900241","article-title":"A randomized trial of Rosuvastatin in the prevention of venous thromboembolism","volume":"360","author":"Glynn","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high senstivity C-reactive protein after an initially elevated concentration: The JUPITER study","volume":"55","author":"Glynn","year":"2008","journal-title":"Clinical Chemistry"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"488","DOI":"10.7326\/0003-4819-152-8-201004200-00005","article-title":"Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: Exploratory analysis of a randomised trial","volume":"152","author":"Glynn","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0053|cit53","unstructured":"Jha AK Hwang U Keyhani S Statins lower the risk of first cardiovascular event in patients with high C-reactive protein and normal LDL cholesterol (outcomes research in review) Journal of Clinical Outcomes Management 2009 16 1 09, 12 13"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.amjcard.2009.07.033","article-title":"Another look at the results of JUPITER trial","volume":"104","author":"Kappagoda","year":"2009","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0055|cit55","first-page":"104","article-title":"A randomised study of efficacy of statins in the prevention of venous thromboembolism","volume":"43","author":"Kerst","year":"2009","journal-title":"Geneesmiddelenbulletin"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/eurheartj\/ehq370","article-title":"Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk >=5 or Framingham risk >20%: Post hoc analyses of the JUPITER trial requested by European health authorities","volume":"32","author":"Koenig","year":"2011","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1753944709337056","article-title":"The JUPITER study, CRP screening and agressive statin therapy-implications for the primary prevention of cardiovascular disease","volume":"3","author":"Kones","year":"2009","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"issue":"9","key":"10.1002\/14651858.CD004816.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","article-title":"Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: Results from the justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Nissen SE The Jupiter trial; Key findings, controversies and implications Current Cardiology Reports 2009 11 2 81 2","DOI":"10.1007\/s11886-009-0013-0"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3810\/pgm.2009.05.2010","article-title":"The gravity of JUPITER ( Justification for the use of statins in primary prevention: An intervention trial evaluating Rosuvastatin)","volume":"121","author":"O'Keefe","year":"2009","journal-title":"Postgraduate Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3111\/13696998.2010.499758","article-title":"Cost-effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial","volume":"13","author":"Ohsfeldt","year":"2010","journal-title":"Journal of Medical Economics"},{"issue":"9670","key":"10.1002\/14651858.CD004816.pub5-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of Rosuvastatin: A prospective study of JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"issue":"21","key":"10.1002\/14651858.CD004816.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-Reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004816.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.amjcard.2007.09.072","article-title":"Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein","volume":"100","author":"Ridker","year":"2007","journal-title":"American Journal of Cardiology"},{"issue":"9738","key":"10.1002\/14651858.CD004816.pub5-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(10)60713-1","article-title":"HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analyis from JUPITER trial","volume":"376","author":"Ridker","year":"2010","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD004816.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2010.08.025","article-title":"The JUPITER trial: Responding to the critics","volume":"106","author":"Ridker","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","article-title":"Efficacy of Rosuvastatin among men and women with moderate chronic kidney disease and elevated high sensitvity C-reactive protein","volume":"55","author":"Ridker","year":"2010","journal-title":"Journal of American College of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: An intervention trial evaluating Rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0069|cit69","first-page":"447","article-title":"Rosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk: Implications of the Justification for use of statins in prevention: An intervention trial evaluating Rosuvastatin (JUPITER) trial for \"intermediate risk\"","volume":"3","author":"Ridker","year":"2010","journal-title":"Circulation:Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high sensitivity C-reactive protein; Rationale and design of the JUPITER trial","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1161\/CIRCOUTCOMES.109.868299","article-title":"The JUPITER trial: results, controversies, and implications for prevention","volume":"2","author":"Ridker","year":"2009","journal-title":"Circulation Cardiovascular Quality & Outcomes"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0072|cit72","unstructured":"Rosenstein R Parra D Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0073|cit73","unstructured":"Segura J Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2459\/JCM.0b013e32834102ab","article-title":"The risks of new hypothesis: why did JUPITER patients have twice the predicted event rates of reduction","volume":"12","author":"Sgueglia","year":"2011","journal-title":"Journal of Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0075|cit75","doi-asserted-by":"crossref","unstructured":"Slejko JF Page RL Sullivan PW Statin therapy is cost-effective for vascular event prevention in adults with elevated C-reactive protein: Implications of Jupiter Journal of the American College of Cardiology 2010","DOI":"10.1016\/S0735-1097(10)61230-2"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0076|cit76","unstructured":"Sniderman AD Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial Lancet"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0077|cit77","first-page":"91","article-title":"The JUPITER trial: How will it change clinical practice","volume":"10","author":"Watson","year":"2009","journal-title":"Reviews in Cardiovascular Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1161\/01.CIR.92.7.1758","article-title":"Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries","volume":"92","author":"Salonen","year":"1995","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Bots M Palmer M Grobbee D Crouse J O'Leary D C-Reactive protein lowering with rosuvastatin in the METEOR study Atherosclerosis Supplement 2009","DOI":"10.1016\/S1567-5688(09)71073-6"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2796.2009.02073.x","article-title":"Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study","volume":"265","author":"Bots","year":"2009","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0081|cit81","doi-asserted-by":"crossref","unstructured":"Crouse J Effects of statin therapy on the carotid artery Atherosclerosis Supplement 2009","DOI":"10.1016\/S1567-5688(09)70047-9"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1185\/030079907X178711","article-title":"Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: Baseline data from the METEOR study","volume":"23","author":"Grobbee","year":"2007","journal-title":"Current Medical Research and Opinion"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial","volume":"297","author":"Raichlen","year":"2007","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1001\/jama.297.12.1376","article-title":"Primary prevention of atherosclerotic cardiovascular disease. The high public burden of low individual risk","volume":"297","author":"Lauer","year":"2007","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2796.2010.02230.x","article-title":"C-reactive protein lowering with rosuvastatin in the METEOR study","volume":"268","author":"Peters","year":"2010","journal-title":"Journal of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0086|cit86","unstructured":"Sanne Peters S Den Ruiters H Completeness of carotid intima-media thickness measurements. Analaysis of the METEOR study European Journal of Cardiovascular Prevention and Rehabilitation 2011"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(10)62174-5","article-title":"C-reactive protein concentration and the vasculr benefits of statin theray: an analysis of 20,536 patients of the Heart Protection Study","volume":"377","author":"Heart Protection Study Collaborative Group","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","article-title":"Effects of 11 year mortality and morbidiity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial","volume":"378","author":"Heart Protection Study Collaborative Group","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of Choleterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomised trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes","volume":"45","author":"Heart Protection Study Collaborative Group","year":"2007","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCOUTCOMES.108.808469","article-title":"Statin cost-effectiveness in the United States for people at different vascular risk levels","volume":"2","author":"Heart Protection Study Collaborative Group","year":"2009","journal-title":"Circulation-Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-9-6","article-title":"Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people","volume":"9","author":"MRC\/BHF Heart Protection Study Collaborative Group","year":"2009","journal-title":"BMC Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"c1197","DOI":"10.1136\/bmj.c1197","article-title":"Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial","volume":"340","author":"Mancia","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.STR.0000147041.00840.59","article-title":"Different effects of anti-hypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS- a randomised double blind trial","volume":"35","author":"Zanchetti","year":"2004","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbinuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"issue":"supplement 92","key":"10.1002\/14651858.CD004816.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1111\/j.1523-1755.2004.09227.x","article-title":"Framingham score and microalbuminuria: combined future targets for primary prevention?","volume":"66","author":"Asselbergs","year":"2004","journal-title":"Kidney international.Supplement"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2006.11.011","article-title":"Long-term effects of pravastatin and fosinopril on peripheral endothelial function in albuminuric subjects","volume":"196","author":"Asselbergs","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1136\/bmj.315.7122.1577","article-title":"The West of Scotland Coronary Prevention Study: economic benefit analysis of primary prevention with pravastatin","volume":"315","author":"Caro","year":"1997","journal-title":"BMJ"},{"issue":"15","key":"10.1002\/14651858.CD004816.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland coronary prevention study","volume":"357","author":"Ford","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jelectrocard.2006.05.003","article-title":"The value of the electrocardiogram in risk assessment in primary prevention: Experience from the West Scotland Coronary Prevention Study","volume":"40","author":"Macfarlane","year":"2007","journal-title":"Journal of Electrocardiology"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1524-4733.1998.120120.x","article-title":"Prevention of heart disease: is LDL reduction the outcome of choice? No, there is more","volume":"1","author":"Sheperd","year":"1998","journal-title":"Value In Health"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.atherosclerosissup.2007.02.001","article-title":"Cholesterol lowering with statins: How WOSCOPS confounded the skeptics","volume":"s8","author":"Shepherd","year":"2007","journal-title":"Atherosclerosis Supplements"},{"issue":"20","key":"10.1002\/14651858.CD004816.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"33","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0895-4356(92)90068-X","article-title":"A coronary primary prevention study of Scottish men aged 45-64 years: trial design","volume":"45","author":"The West of Scotland Coronary Prevention Study Group","year":"1992","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0002-9149(96)00863-6","article-title":"Baseline risk factors and their associations with outcome in the West of Scotland Coronary Prevention Study","volume":"79","author":"The West of Scotland Coronary Prevention Study Group","year":"1997","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/oxfordjournals.eurheartj.a015165","article-title":"Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study","volume":"18","author":"The West of Scotland Coronary Prevention Study Group","year":"1997","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0140-6736(96)04292-4","article-title":"West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials","volume":"348","author":"West of Scotland Coronary Prevention Group","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","article-title":"Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)","volume":"97","author":"West of Scotland Coronary Prevention Study Group","year":"1998","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1042\/CS20060033","article-title":"Atorvastatin normalizes endothelial function in healthy smokers","volume":"111","author":"Agewall","year":"2006","journal-title":"Clinical Science"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin versus usual care","volume":"288","author":"The Anti-hypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0111|cit111","unstructured":"Ames P Sokoll K Maviver H Batuca J Lopez L Effect of atorvastatin on inflammatory markers, nitric oxide meatbolites and carotid intima media thickness in systemic lupus erythematosus Journal of Thrombosis and Haemostasis 2011 57th Annual SSC meeting"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199502233320802","article-title":"The effect of cholesterol-lowering and anti-oxidant therapy on endothelium-dependent coronary vasomotion","volume":"332","author":"Anderson","year":"1993","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0113|cit113","first-page":"150","article-title":"Ethnic variation in lipid lowering in response to a statin (Evirest): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)","volume":"21","author":"Chapman","year":"2011","journal-title":"Ethnicity and Disease"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/HJH.0b013e328342c8f7","article-title":"Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid- Lowering arm.","volume":"29","author":"Collier","year":"2011","journal-title":"Journal of Hypertension"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004816.pub5-BIB0115|cit115","first-page":"S1","article-title":"Anglo-Scandinavian Cardiac Outcomes Trial ASCOT. Main protocol summary & sub-study protocols","volume":"15","author":"O'Brien","year":"2001","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00392-003-0967-7","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cariac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"92","author":"Sever","year":"2003","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial","volume":"19","author":"Sever","year":"2001","journal-title":"Journal of Hypertension"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0119|cit119","first-page":"165","article-title":"Statin therapy for hypertensive patients","volume":"124","author":"Svilaas","year":"2004","journal-title":"Tidsskrift for Den Norske Laegeforening"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Chan KL Ni A Tam J Sochowski R Dumesnil JG Giannocaro JP Interaction between rosuvastatin and high sensitivity c-reactive protein on progression of aortic stenosis Journal of the American College of Cardiology Conference 2010","DOI":"10.1016\/S0735-1097(10)61396-4"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/CIRCULATIONAHA.109.900027","article-title":"Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (Astronomer) trial","volume":"121","author":"Chan","year":"2010","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1365-2796.1998.00350.x","article-title":"Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease","volume":"244","author":"Bak","year":"1998","journal-title":"Journal of Internal Medicine."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1161\/01.CIR.103.13.1721","article-title":"Low dose metaprolol CR\/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study","volume":"103","author":"Hedblad","year":"2001","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD004816.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/0002-9149(91)90182-K","article-title":"Long-term safety and efficacy profile of simvastatin","volume":"68","author":"Boccuzzi","year":"1991","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0125|cit125","first-page":"345","article-title":"Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients","volume":"33","author":"Branchi","year":"1995","journal-title":"International Journal of Clinical Pharmacology & Therapeutics."},{"issue":"s","key":"10.1002\/14651858.CD004816.pub5-BIB0126|cit126","first-page":"20","article-title":"PLAC 2: effects of pravastatin on progression of carotid atherosclerosis and clinical events","volume":"14","author":"Byington","year":"1993","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0127|cit127","unstructured":"Carotid Atorvastatin Study in Hyperlipidemic Post-MEnopausal Women: a Randomised Evaluation of atorvastatin versus placebo (CASHMERE). Protocol A2581051 PhRMA Web Synopsis 2007"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0021-9150(93)90049-Z","article-title":"Hypercholesterolemia in non-insulin-dependent diabetes mellitus: different effect of simvastatin on VLDL and LDL cholesterol levels","volume":"99","author":"Cassader","year":"1993","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1253\/circj.CJ-08-0135","article-title":"Rationale and design of the carotid plaque in human for all evaluations with aggressive rosuvastatin therapy (CHALLENGER trial): evaluation by magnetic resonance imaging","volume":"73","author":"Miyauchi","year":"2009","journal-title":"Circulation Journal"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.28.4.647","article-title":"Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects","volume":"28","author":"Chan","year":"1996","journal-title":"Hypertension."},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.bone.2009.12.023","article-title":"Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia","volume":"46","author":"Chuengsamarn","year":"2010","journal-title":"Bone"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"99","DOI":"10.5551\/jat.9.99","article-title":"Prognosis of hypercholesterolemic patients taking pravastatin for five years: the Chiba Lipid Intervention Program (CLIP) study","volume":"9","author":"Saito","year":"2002","journal-title":"Journal of Athersclerosis and Thrombosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/thx.2010.138990","article-title":"Simvastatin in the treatment of asthma: lack of steroid-sparing effect","volume":"65","author":"Cowan","year":"2010","journal-title":"Thorax"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"799","DOI":"10.4065\/83.7.799","article-title":"Placing COURAGE in context: review of the recent literature on managing stable coronary artery disease","volume":"83","author":"Coylewright","year":"2008","journal-title":"Mayo Clinic Proceedings"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Archives of Internal Medicine."},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1997.tb00971.x","article-title":"Effect of pharmacologic lipid lowering on health-related quality of life in older persons: Results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study","volume":"45","author":"Santanello","year":"1997","journal-title":"Journal of the American Geriatric Society"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin with that of lovastatin, pravastatin, simvastatin and fluvastatin in patients With hypercholesterolemia (the CURVES Study)","volume":"81","author":"Jones","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0735-1097(99)00018-2","article-title":"Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile","volume":"33","author":"Dangas","year":"1999","journal-title":"Journal of the American College of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/S0002-9149(97)00174-4","article-title":"Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia","volume":"79","author":"Davidson","year":"1997","journal-title":"American Journal of Cardiology"},{"issue":"5-6","key":"10.1002\/14651858.CD004816.pub5-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1440-1681.2001.03458.x","article-title":"Effect of anti-oxidant treatment and cholesterol lowering on resting arterial tone, metabolic vasodilation and endothelial function in the human forearm: a randomized, placebo-controlled study","volume":"28","author":"Duffy","year":"2001","journal-title":"Clinical & Experimental Pharmacology & Physiology."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1161\/01.CIR.89.6.2519","article-title":"Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia","volume":"89","author":"Egashira","year":"1994","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1998.00294.x","article-title":"Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care","volume":"243","author":"Eriksson","year":"1998","journal-title":"Journal of Internal Medicine."},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archinte.1991.00400010067008","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia","volume":"151","author":"Bradford","year":"1991","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub5-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"44B","DOI":"10.1016\/0002-9149(90)90440-C","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia","volume":"66","author":"Bradford","year":"1990","journal-title":"American Journal of Cardiology."},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","article-title":"Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up","volume":"74","author":"Bradford","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"1B","key":"10.1002\/14651858.CD004816.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1016\/0002-9343(91)90052-Y","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia","volume":"91","author":"Bradford","year":"1991","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.amjcard.2009.04.008","article-title":"Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease","volume":"104","author":"Faergeman","year":"2009","journal-title":"American Journal of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0735-1097(01)01783-1","article-title":"Effects of probucal and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka atherosclerosis trial (FAST)","volume":"39","author":"Sawayama","year":"2002","journal-title":"Journal of the American College of Cardiology"},{"issue":"37","key":"10.1002\/14651858.CD004816.pub5-BIB0149|cit149","first-page":"1736","article-title":"Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study","volume":"123","author":"Ferrari","year":"1993","journal-title":"Schweizerische Medizinische Wochenschrift [Journal Suisse de Medecine]"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1463-1326.2000.00106.x","article-title":"Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia","volume":"2","author":"Gentile","year":"2000","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0002-9149(97)89140-0","article-title":"The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg\/dl","volume":"77","author":"Glasser","year":"1996","journal-title":"The American Journal Of Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1157\/13113929","article-title":"Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia","volume":"60","author":"G\u00f3mez-Garc\u00eda","year":"2007","journal-title":"Revista Espanola de Cardiologia"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11745-008-3265-3","article-title":"Reduction of heat shock protein antibody levels by statin therapy","volume":"44","author":"Guisasola","year":"2009","journal-title":"Lipids"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0021-9150(01)00765-1","article-title":"Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reducatase inhibitor, of patients with heterozygous familial hypercholesterolemia","volume":"163","author":"Noji","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0155|cit155","unstructured":"Hongo M Kumazaki S Izawa A Kasai H Tanita T Rosuvastatin improves arterial stiffness in hypertensive patients with dyslipidemia European Heart Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ndt\/15.5.684","article-title":"Effects of atorvastatin on dyslipidemia in uraemic patients on peritoneal dialysis","volume":"15","author":"Hufnagel","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0011-393X(96)80050-6","article-title":"Efficacy and safety of simvastatin in current clinical practice: The Italian Family Physician Simvastatin Study","volume":"57","author":"Cattin","year":"1996","journal-title":"Current Therapeutic Research"},{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0158|cit158","first-page":"988","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post hoc analysis of the ALERT study","volume":"4","author":"Fellstrom","year":"2006","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0159|cit159","first-page":"221","article-title":"Effect of intensive lipid lowering therapy with rosuvastatin of carotid intima-media thickness in Japanese patients: Justification of Atherosclorosis Regression Treatment (JART) study","volume":"76","author":"Hohara","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.atherosclerosis.2009.03.029","article-title":"Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)","volume":"206","author":"Oikawa","year":"2009","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1291\/hypres.30.119","article-title":"Effects of hypertension and type 2 diabetes mellitus on the risk of total cardiovascular events in Japanese patients with hypercholesterolemia: implications from the Japan Lipid Intervention Trial (J-LIT)","volume":"30","author":"Kita","year":"2007","journal-title":"Hypertension Research - Clinical & Experimental"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/clc.4960140211","article-title":"Once-daily pravastatin in patients with primary hypercholesterolemia: a dose-response study","volume":"14","author":"Jones","year":"1991","journal-title":"Clinical Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/14728220903023866","article-title":"Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: Modification by triglycerides and cholesteryl ester transfer protein","volume":"13","author":"Zwang","year":"2009","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0021-9150(00)80166-5","article-title":"Abstract at XIIth International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29 2000. Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS)","volume":"151","author":"Sasaki","year":"2000","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5551\/jat1994.3.95","article-title":"A coronary primary intervention study of Japanese men: study design, implementation and baseline data","volume":"3","author":"The Kyushu Lipid Intervention Study Group","year":"1996","journal-title":"Journal of Atherosclerosis & Thrombosis"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1253\/circj.CJ-09-0243","article-title":"Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients","volume":"74","author":"Kojima","year":"2010","journal-title":"Circulation Journal"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1001\/archinte.162.12.1395","article-title":"Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study","volume":"162","author":"Lemaitre","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0168|cit168","first-page":"588","article-title":"Effects of rosuvasatin on left ventricular cardiac function, arteriosclerotic plaque and high sensitive C-reactive protein in hyepertensive patienrs with mild LdL-C elevation","volume":"30","author":"Lin","year":"2010","journal-title":"Journal of Southern Medical University (China)"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2288-10-27","article-title":"Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study","volume":"10","author":"Cui","year":"2010","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0170|cit170","first-page":"4","article-title":"Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA [Russian]","volume":"48","author":"Mareev","year":"2008","journal-title":"Kardiologiia"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1161\/01.CIR.0000050380.64025.07","article-title":"Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease","volume":"107","author":"McDermott","year":"2003","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1253\/circj.72.538","article-title":"Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia","volume":"72","author":"Mizuguchi","year":"2008","journal-title":"Circulation Journal"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1161\/01.CIR.0000090686.57897.F5","article-title":"Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease","volume":"108","author":"Mohler","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000215939","article-title":"Statins for asymptomatic middle cerebral artery stenosis: The Regression of Cerebral Artery Stenosis study","volume":"28","author":"Mok","year":"2009","journal-title":"Cerebrovascular Diseases"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"American Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD004816.pub5-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0002-9149(97)00695-4","article-title":"Effects of lovastatin on the immune system","volume":"80","author":"Muldoon","year":"1997","journal-title":"American Journal of Cardiology."},{"issue":"Suppl. 71","key":"10.1002\/14651858.CD004816.pub5-BIB0177|cit177","first-page":"S","article-title":"Simvastatin in nephrotic syndrome","volume":"56","author":"Olbricht","year":"1999","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000023559","article-title":"Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause","volume":"53","author":"Ohta","year":"2000","journal-title":"Hormone Research."},{"issue":"1-2","key":"10.1002\/14651858.CD004816.pub5-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0021-9150(97)88689-3","article-title":"Abstract of the 11th Internationial Symposium on Atherosclerosis Paris, 5-9 October 1997. 2.P.51 Escape phenomenon during the long-term administration of pravastatin for hyperlipidemia associated with diabetes","volume":"134","author":"Oi","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.mao.0000271673.33683.7b","article-title":"Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: Results of a prospective, randomized, double-blind clinical trial","volume":"28","author":"Olzowy","year":"2007","journal-title":"Otology and Neurotology"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1176\/appi.psy.44.5.412","article-title":"Behavioral implications of lowering cholesterol levels: a double-blind pilot study","volume":"44","author":"Ormiston","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0182|cit182","doi-asserted-by":"crossref","unstructured":"Pavia Lopez A Zamorano J Kim JH Erdine S Al Khadra A Westergaard M Treatment strategies for cardiovascular risk factor management in patients with hypertension and additional risk factors-experiences from the usual care arm of the Crucial trial Journal of Hypertension 2010 p e276-e277","DOI":"10.1097\/01.hjh.0000379016.95320.39"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199907083410202","article-title":"Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease","volume":"341","author":"Pitt","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0735-1097(95)80006-3","article-title":"Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: Report from the Program on the Surgical Control of the Hyperlipidemias (POSCH)","volume":"26","author":"Buchwald","year":"1995","journal-title":"Journal of American College Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00000658-199210000-00001","article-title":"Women in the POSCH trial. Effects of aggressive cholesterol modification in women with coronary heart disease","volume":"216","author":"Buchwald","year":"1992","journal-title":"Annals of Surgery"},{"issue":"11","key":"10.1002\/14651858.CD004816.pub5-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1992.03490110067031","article-title":"Changes in sequential coronary arteriograms and subsequent coronary events","volume":"268","author":"Buchwald","year":"1992","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia","volume":"323","author":"Buchwald","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol\/liter (200 to 300 mg\/dl) plus two additional atherosclerotic risk factors","volume":"72","author":"The Pravastatin Multinational Study Group for Cardiac Risk Patients","year":"1993","journal-title":"American Journal of Cardiology."},{"issue":"6","key":"10.1002\/14651858.CD004816.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0197-2456(02)00228-3","article-title":"Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial","volume":"23","author":"Avorn","year":"2002","journal-title":"Controlled Clinical Trials"},{"issue":"9363","key":"10.1002\/14651858.CD004816.pub5-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(03)12878-4","article-title":"More on PROSPER","volume":"361","author":"Baztan","year":"2003","journal-title":"Lancet"},{"issue":"9259","key":"10.1002\/14651858.CD004816.pub5-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(05)71808-0","article-title":"Dementia and statins. PROSPER study group","volume":"357","author":"Blauw","year":"2001","journal-title":"Lancet"},{"issue":"9346","key":"10.1002\/14651858.CD004816.pub5-BIB0192|cit192","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(02)11650-3","article-title":"High-risk elderly patients PROSPER from cholesterol-lowering therapy","volume":"360","author":"Collins","year":"2002","journal-title":"Lancet"},{"issue":"9355","key":"10.1002\/14651858.CD004816.pub5-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(03)12398-7","article-title":"The PROSPER trial","volume":"361","author":"Fiorenza","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1468-6708-3-8","article-title":"A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): screening experience and baseline characteristics","volume":"3","author":"Shepherd","year":"2002","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.73.4.385","article-title":"Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk","volume":"73","author":"Houx","year":"2002","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry."},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0196|cit196","first-page":"809","article-title":"The PROSPER Study (PROspective study of pravastatin in the elderly at risk)","volume":"57","author":"Kulbertus","year":"2002","journal-title":"Revue Medicale de Liege"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0197|cit197","first-page":"48","article-title":"Pravastatin benefits elderly patients: results of PROSPER study","volume":"14","year":"2003","journal-title":"Cardiovascular Journal of Southern Africa"},{"issue":"9346","key":"10.1002\/14651858.CD004816.pub5-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet."},{"issue":"10","key":"10.1002\/14651858.CD004816.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0002-9149(99)00533-0","article-title":"The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk","volume":"84","author":"Shepherd","year":"1999","journal-title":"American Journal of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1567-5688(03)90003-1","article-title":"Preventing the next event in the elderly: the PROSPER perspective","volume":"4","author":"Shepherd","year":"2003","journal-title":"Atherosclerosis Supplements"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00592-007-0246-6","article-title":"Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus","volume":"44","author":"Safaei","year":"2007","journal-title":"Acta Diabetologica"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub5-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1001\/jama.299.14.1678","article-title":"Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: The SANDS randomized trial","volume":"299","author":"Howard","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD004816.pub5-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1161\/CIRCULATIONAHA.105.568147","article-title":"Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: A multicenter, randomized, double-blind trial","volume":"113","author":"Schmermund","year":"2006","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0204|cit204","unstructured":"Sen K Misra A Kumar A Double blind randomized trial of efficacy of simvastatin on retinopathy in hyperlipidemic diabetic patients Journal of the Association of Physicians of India 2000"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-120-7-199404010-00002","article-title":"Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients","volume":"120","author":"Sprecher","year":"1994","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/107424849700200102","article-title":"Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2mg daily in subjects with primary hypercholesterolemia","volume":"2","author":"Stein","year":"1997","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0002-9149(00)01004-3","article-title":"Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension","volume":"86","author":"Su","year":"2000","journal-title":"American Journal of Cardiology."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0009-8981(01)00589-7","article-title":"A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia","volume":"312","author":"Akira","year":"2001","journal-title":"Clinica Chimica Acta"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0209|cit209","unstructured":"Tarin N Tunan-Fernandez JT Sanz P Espana E Turbi C Statins reduce the incidence of cardiovascular events in postmenopausal women in secondary but not in primary prevention. A retrospective analysis of the Ruth study European Heart Journal 2010"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub5-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/jhh.2010.87","article-title":"Effects of fluvastatin on insulin resistance and cardiac morpholgy in hypertensive patients","volume":"25","author":"Teixeira","year":"2011","journal-title":"Journal of Human Hypertension"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.phrs.2008.04.001","article-title":"Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients","volume":"57","author":"Tekin","year":"2008","journal-title":"Pharmacological Research"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1993.358","article-title":"Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria","volume":"44","author":"Thomas","year":"1993","journal-title":"Kidney International."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(97)11475-1","article-title":"Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk","volume":"351","author":"The Medical Research Council's General Practice Research Framework","year":"1998","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1177\/1352458510369147","article-title":"Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial","volume":"16","author":"Togha","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0215|cit215","first-page":"e205","article-title":"Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins","volume":"14","author":"Tran","year":"2007","journal-title":"Canadian Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/bmj.327.7418.788","article-title":"Taking Simvastatin in the morning compared with in the evening: randomised controlled trial","volume":"327","author":"Wallace","year":"2003","journal-title":"BMJ"},{"issue":"31","key":"10.1002\/14651858.CD004816.pub5-BIB0217|cit217","first-page":"2215","article-title":"Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality","volume":"87","author":"Wu","year":"2007","journal-title":"National Medical Journal of China"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0218|cit218","first-page":"S42","article-title":"Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia","volume":"136","author":"Yu-An","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0219|cit219","first-page":"531","article-title":"Cerivastatin and Pravastatin in the hyperlipoproteinaemia therapy in patients after liver transplantation - Results of a randomised, cross-over study","volume":"38","author":"Zachoval","year":"2000","journal-title":"Zeitschrift fur Gastroenterologie."},{"key":"10.1002\/14651858.CD004816.pub5-BIB0220|cit220","unstructured":"Babes E Babes V Popescu M Rus M Simvastatin therapy and endothelial function in young adults with subclinical atheroslerosis Cardiovascular Research S94"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0140-6736(07)60084-1","article-title":"Are lipid-lowering guidelines evidence-based?","volume":"369","author":"Abramson","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD004816.pub5-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"issue":"9493","key":"10.1002\/14651858.CD004816.pub5-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/heart.89.3.327","article-title":"Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised controlled trials of statins 1990 to 2001","volume":"89","author":"Bartlett","year":"2003","journal-title":"Heart"},{"issue":"38","key":"10.1002\/14651858.CD004816.pub5-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9380","article-title":"The causes and effects of socio-demographic exclusions from clinical trials","volume":"9","author":"Bartlett","year":"2005","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0227|cit227","unstructured":"Beers MH The Merck Manual of Diagnosis and Therapy Http:\/\/www.merck.com (accessed 20 November 2003)"},{"issue":"4","key":"10.1002\/14651858.CD004816.pub5-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1012848","article-title":"Lifetime risks of cardiovascular disease","volume":"366","author":"Berry","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.STR.28.5.946","article-title":"Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors","volume":"28","author":"Blauw","year":"1997","journal-title":"Stroke"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0230|cit230","unstructured":"BMJ Clinical Evidence Default search strategies used for BMJ Clinical Evidence: Embase randomised controlled trial strategy http:\/\/clinicalevidence.bmj.com\/ceweb\/about\/search_filters.jsp"},{"issue":"8","key":"10.1002\/14651858.CD004816.pub5-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.amjmed.2004.04.022","article-title":"Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials","volume":"117","author":"Briel","year":"2004","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"b2376","DOI":"10.1136\/bmj.b2376","article-title":"The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials","volume":"338","author":"Brugts","year":"2009","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/bmj.303.6797.276","article-title":"Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations","volume":"303","author":"Chen","year":"1991","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","article-title":"Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes","volume":"57","author":"Cheung","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials","volume":"376","author":"CTT Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0236|cit236","first-page":"doi:10.1016\/S01","article-title":"The effects of lowering LDL cholesterolwith statin therapy in people at low risk of vascular disease: meta-analysis of individualdata from 27 randomised trials","volume":"378","author":"Cholesterol Treatment Trialists (CTT) Collaboration\u00a0\u00a0","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0237|cit237","first-page":"e29849","article-title":"Lack of effect of lowering LDLcholesterol on cancer: meta-analysis of individual data from 175,000 people in 27randomised trials of statin therapy","volume":"7 (1)","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jama.1992.03480010078028","article-title":"Plasma cholesterol concentrations and mortality in the Whitehall study","volume":"267","author":"Davey Smith","year":"1992","journal-title":"JAMA"},{"issue":"13","key":"10.1002\/14651858.CD004816.pub5-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMp0805953","article-title":"Storm over statins--the controversy surrounding pharmacologic treatment of children","volume":"359","author":"Ferranti","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0241|cit241","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/qshc.7.4.232","article-title":"Cholesterol and heart disease: screening and treatment","volume":"7","author":"Ebrahim","year":"1998","journal-title":"Quality in Health Care"},{"issue":"19","key":"10.1002\/14651858.CD004816.pub5-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3190","article-title":"What role for statins? A review and economic model","volume":"3","author":"Ebrahim","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"7557","key":"10.1002\/14651858.CD004816.pub5-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.38855.610324.80","article-title":"Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study","volume":"333","author":"Ebrahim","year":"2006","journal-title":"BMJ"},{"issue":"9841","key":"10.1002\/14651858.CD004816.pub5-BIB0244|cit244","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(12)60694-1","article-title":"Statins for all by the age of 50?","volume":"380","author":"Ebrahim","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","article-title":"Selected major risk factors and global and regional burden of disease","volume":"360","author":"Ezzati","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1377\/hlthaff.26.1.13","article-title":"Reducing the growing burden of cardiovascular disease in the developing world","volume":"26","author":"Gaziano","year":"2007","journal-title":"Health Affairs"},{"issue":"10","key":"10.1002\/14651858.CD004816.pub5-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0828-282X(09)70715-9","article-title":"2009 Canadian Cardiovascular Society\/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations","volume":"25","author":"Genest","year":"2009","journal-title":"Canadian Journal of Cardiology"},{"issue":"15","key":"10.1002\/14651858.CD004816.pub5-BIB0248|cit248","first-page":"1180","article-title":"Effects of statin on energy and fatigue and exertion: results from a randomised controlled trial","volume":"172","author":"Dimsdale","year":"2012","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0249|cit249","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"c2197","DOI":"10.1136\/bmj.c2197","article-title":"Unintended effects of statins in men and women in England and wales: population based cohort study using the QResearch database.","volume":"340","author":"Hippisley-Cox","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/ije\/26.6.1191","article-title":"Serum total cholesterol and risk of hospitalisation, and death from respiratory disease","volume":"26","author":"Iribarren","year":"1997","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1046\/j.0306-5251.2001.01478.x","article-title":"Statins for primary prevention: at what coronary risk is safety assured?","volume":"52","author":"Jackson","year":"2001","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/oxfordjournals.aje.a009314","article-title":"Reduced cholesterol is associated with recent minor illness. The CARDIA study","volume":"146","author":"Jacobs","year":"1997","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0254|cit254","unstructured":"Jepson R The effectiveness of Interventions to change health-related behaviours: a review of reviews Medical Research Council Social & Public Health Sciences Unit. MRC Social & Public Health Sciences Unit Occasional Paper No 3"},{"issue":"25","key":"10.1002\/14651858.CD004816.pub5-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: A systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/oxfordjournals.aje.a009830","article-title":"Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: A meta-meta-analysis","volume":"149","author":"Katerndahl","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0257|cit257","doi-asserted-by":"publisher","first-page":"28 November 201","DOI":"10.1016\/S0140-6736(12)61426-3","article-title":"Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study","volume":"Online publicat","author":"Kokkinos","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD004816.pub5-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archinte.1994.00420050081008","article-title":"Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study","volume":"154","author":"LaRosa","year":"1994","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials","volume":"282","author":"LaRosa","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.326.7404.1423","article-title":"Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1161\/CIRCULATIONAHA.110.986349","article-title":"Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era","volume":"124","author":"Lazar","year":"2011","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0262|cit262","unstructured":"Lefebvre C Mcdonald S Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE Paper presented at the Fourth International Cochrane Colloquium 20-24 Oct 1996 1996"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0263|cit263","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies: In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011"},{"issue":"9604","key":"10.1002\/14651858.CD004816.pub5-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/S0140-6736(07)61699-7","article-title":"Prevention of cardiovascular disease in high-risk individuals in low-income and middle-income countries: health effects and costs","volume":"370","author":"Lim","year":"2007","journal-title":"Lancet"},{"issue":"7555","key":"10.1002\/14651858.CD004816.pub5-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.38849.487546.DE","article-title":"Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modeling study","volume":"332","author":"Manuel","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD004816.pub5-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/qjmed\/hcq165","article-title":"Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials","volume":"104","author":"Mills","year":"2011","journal-title":"QJM"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well\u00adbeing","volume":"108","author":"Muldoon","year":"2000","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bmj.322.7277.11","article-title":"Cholesterol reduction and non\u00adillness mortality: meta\u00adanalysis of randomised clinical trials","volume":"322","author":"Muldoon","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0269|cit269","unstructured":"National Institute for Health and Clinical Excellence Technology Appraisal TA94: Statins for the prevention of cardiovascular events in patients at increased risk of developing cardiovascular disease or those with established cardiovascular disease. 2006 http:\/\/www.nice.org.uk\/TA094 [accessed 10.10.2010]"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmj.321.7267.983","article-title":"Use of lipid lowering drugs for primary prevention of coronary heart disease: meta\u00adanalysis of randomised trials","volume":"321","author":"Pignone","year":"2000","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0272|cit272","first-page":"1829","article-title":"Collaborative meta-analysis of 61 studies of vascular risk factors (blood cholesterol, blood pressure, body mass index, diabetes) and cause-specific mortality","volume":"370","author":"Prospective Studies Collaboration","year":"2007","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1001\/archinternmed.2010.182","article-title":"Statins and all-cause mortality in high-risk primary prevention. A meta-analysis of 11 randomized controlled trials involving 65,229 participants","volume":"170","author":"Ray","year":"2010","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0274|cit274","first-page":"1345","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias. The Task Force on the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"European Heart Journal"},{"issue":"9716","key":"10.1002\/14651858.CD004816.pub5-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statin-related adverse events: a meta-analysis","volume":"28","author":"Silva","year":"2006","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0277|cit277","first-page":"99-109","article-title":"\u00a0Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials.","volume":"67","author":"Smeeth","year":"2008","journal-title":"British Joutnal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"doi: 10.1136\/bm","DOI":"10.1136\/bmj.e3802","article-title":"Improving vascular health: are pills the answer?","volume":"344","author":"Smeeth","year":"2012","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","volume-title":"Systematic reviews in health care. Meta-analysis in context","author":"Sterne","year":"2001"},{"issue":"21","key":"10.1002\/14651858.CD004816.pub5-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0281|cit281","unstructured":"Jauca C Wright JM Do statins have a role in primary prevention? Therapeutics Letter 2003 48"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0282|cit282","unstructured":"Wright JM Do statins have a role in primary prevention? An update Therapeutics Letter 2010 77"},{"issue":"12","key":"10.1002\/14651858.CD004816.pub5-BIB0283|cit283","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5414\/CPP41567","article-title":"Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials","volume":"41","author":"Vrecer","year":"2003","journal-title":"International Journal of Clinical Pharmacology Therapeutics"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/bmj.328.7436.385","article-title":"Variations and increase in use of statins across Europe","volume":"328","author":"Walley","year":"2004","journal-title":"BMJ"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub5-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11140","article-title":"A systematic review and economic evaluation of statins for the prevention of coronary events","volume":"11","author":"Ward","year":"2007","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0286|cit286","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bmj.313.7049.75","article-title":"Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration","volume":"313","author":"Wardle","year":"1996","journal-title":"BMJ"},{"issue":"14","key":"10.1002\/14651858.CD004816.pub5-BIB0287|cit287","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.jacc.2010.10.047","article-title":"Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials","volume":"57","author":"Waters","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0288|cit288","volume-title":"The World Health report. Accessed online at www.who.int\/cardiovascular_diseases\/en\/2008 September 30th","year":"2008"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0289|cit289","volume-title":"2008-2013 Action Plan for the global strategy for the prevention and control of noncommunicable diseases","author":"World Health Organization","year":"2008"},{"issue":"13","key":"10.1002\/14651858.CD004816.pub5-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archinte.164.13.1427","article-title":"Effectiveness of statin therapy in adults with coronary heart disease","volume":"164","author":"Wilt","year":"2004","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD004816.pub5-BIB0291|cit291","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1161\/hc4601.099487","article-title":"Global burden of cardiovascular diseases. Part 1: General considerations, the epidemic transition, risk factors, and impact of urbanisation","volume":"104","author":"Yusuf","year":"2001","journal-title":"Circulation"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0292|cit292","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004816.pub3","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004816.pub5-BIB0293|cit293","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004816.pub4","article-title":"Statins for the primary prevention of cardiovascular disease","author":"Taylor","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004816.pub5\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T04:54:35Z","timestamp":1668401675000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004816.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":293,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004816.pub5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717985686.793476549","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}